OncoSynergy Launches Phase I Trial for Patients With Recurrent Glioblastoma
OncoSynergy, a patient-focused biotech startup founded by physicians trained in neurosurgery has opened enrollment in their phase 1 trial which will study OS2966, a novel therapeutic antibody, for treatment of…